[PMID]: | 28687708 |
[Au] Autor: | Amyere M; Revencu N; Helaers R; Pairet E; Baselga E; Cordisco M; Chung W; Dubois J; Lacour JP; Martorell L; Mazereeuw-Hautier J; Pyeritz RE; Amor DJ; Bisdorff A; Blei F; Bombei H; Dompmartin A; Brooks D; Dupont J; González-Enseñat MA; Frieden I; Gérard M; Kvarnung M; Hanson-Kahn AK; Hudgins L; Léauté-Labrèze C; McCuaig C; Metry D; Parent P; Paul C; Petit F; Phan A; Quere I; Salhi A; Turner A; Vabres P; Vicente A; Wargon O; Watanabe S; Weibel L; Wilson A; Willing M; Mulliken JB; Boon LM; Vikkula M |
[Ad] Endereço: | From Human Molecular Genetics, de Duve Institute, Université catholique de Louvain, Brussels, Belgium (M.A., R.H., M.V.); Center for Human Genetics, Cliniques Universitaires St Luc, Université catholique de Louvain, Brussels, Belgium (N.R.); Université catholique de Louvain, Brussels, Belgium (E.P.) |
[Ti] Título: | Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling. |
[So] Source: | Circulation;136(11):1037-1048, 2017 Sep 12. |
[Is] ISSN: | 1524-4539 |
[Cp] País de publicação: | United States |
[La] Idioma: | eng |
[Ab] Resumo: | BACKGROUND: Most arteriovenous malformations (AVMs) are localized and occur sporadically. However, they also can be multifocal in autosomal-dominant disorders, such as hereditary hemorrhagic telangiectasia and capillary malformation (CM)-AVM. Previously, we identified mutations in 50% of patients with CM-AVM. Herein we studied non-RASA1 patients to further elucidate the pathogenicity of CMs and AVMs. METHODS: We conducted a genome-wide linkage study on a CM-AVM family. Whole-exome sequencing was also performed on 9 unrelated CM-AVM families. We identified a candidate gene and screened it in a large series of patients. The influence of several missense variants on protein function was also studied in vitro. RESULTS: We found evidence for linkage in 2 loci. Whole-exome sequencing data unraveled 4 distinct damaging variants in in 5 families that cosegregated with CM-AVM. Overall, screening of detected 47 distinct mutations in 54 index patients: 27 led to a premature stop codon or splice-site alteration, suggesting loss of function. The other 20 are nonsynonymous variants that result in amino acid substitutions. In vitro expression of several mutations confirmed loss of function of EPHB4. The clinical features included multifocal CMs, telangiectasias, and AVMs. CONCLUSIONS: We found mutations in patients with multifocal CMs associated with AVMs. The phenotype, CM-AVM2, mimics -related CM-AVM1 and also hereditary hemorrhagic telangiectasia. -encoded p120RASGAP is a direct effector of EPHB4. Our data highlight the pathogenetic importance of this interaction and indicts EPHB4-RAS-ERK signaling pathway as a major cause for AVMs. |
[Mh] Termos MeSH primário: |
Malformações Arteriovenosas/diagnóstico Malformações Arteriovenosas/genética Capilares/anormalidades Mutação em Linhagem Germinativa/genética Sistema de Sinalização das MAP Quinases/fisiologia Mancha Vinho do Porto/diagnóstico Mancha Vinho do Porto/genética Receptor EphB4/genética Proteína p120 Ativadora de GTPase/genética
|
[Mh] Termos MeSH secundário: |
Bases de Dados Genéticas Feminino Estudo de Associação Genômica Ampla/métodos Seres Humanos Masculino Linhagem
|
[Pt] Tipo de publicação: | JOURNAL ARTICLE |
[Nm] Nome de substância:
| 0 (RASA1 protein, human); 0 (p120 GTPase Activating Protein); EC 2.7.10.1 (Receptor, EphB4) |
[Em] Mês de entrada: | 1710 |
[Cu] Atualização por classe: | 171003 |
[Lr] Data última revisão:
| 171003 |
[Sb] Subgrupo de revista: | AIM; IM |
[Da] Data de entrada para processamento: | 170709 |
[St] Status: | MEDLINE |
[do] DOI: | 10.1161/CIRCULATIONAHA.116.026886 |
|
|